Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Syndax Pharmaceuticals (SNDX) granted inducement stock options for up to 175,000 shares of common stock to nineteen new employees on September 1, 2026, under its 2023 Inducement Plan.

Rhea-AI Summary

Syndax Pharmaceuticals (SNDX) granted inducement stock options for up to 175,000 shares of common stock to nineteen new employees on September 1, 2026, under its 2023 Inducement Plan.

The options vest over four years, with 25% vesting after one year and the remaining 75% vesting in equal monthly installments over the following 36 months, contingent on continued service.

News Explained

On September 1, 2026, Syndax granted options to purchase up to 175,000 shares to 19 new employees; the release describes a grant rather than an issuance, so any dilution is prospective: issuing the shares would increase total share count and reduce existing holders’ percentage ownership.

Market Context

The August 5 inducement-grant announcement was followed by a -0.8% 24-hour move, providing a direct ...

Analysis

The August 5 inducement-grant announcement was followed by a -0.8% 24-hour move, providing a direct historical comparator. Recent insider activity was net selling; grant size and vesting terms remain the key distinctions.

Key Figures

Shares covered: 175,000 shares New employees: 19 employees Vesting period: 4 years +3 more

6 metrics

Shares covered 175,000 shares Inducement awards granted September 1, 2026

New employees 19 employees Recipients of inducement awards

Vesting period 4 years Stock option vesting schedule

Initial vesting 25% Vests on the one-year anniversary

Monthly vesting 1/48th Underlying shares vest monthly thereafter

Monthly vesting period 36 months Period following the one-year anniversary

Historical Context

5 past events · Latest: Sep 01 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Sep 01	Investor conferences	Positive	+4.2%	Announced participation in two September investor conferences in New York
Aug 05	Inducement grants	Neutral	-0.8%	Granted inducement options covering 59,250 shares to five new employees
Aug 04	Second-quarter earnings	Positive	+4.4%	Reported revenue growth and narrowed first-half net loss
Jul 28	Earnings scheduling	Neutral	-4.3%	Scheduled second-quarter results and conference call for August 4
Jul 14	Pipeline update	Positive	+5.4%	Outlined new pipeline assets and multiple clinical development programs

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

SNDX's operating, pipeline, and conference announcements were followed by gains, while scheduling and inducement notices were followed by declines.

Key Terms

inducement awards, NASDAQ Listing Rule 5635(c)(4), menin inhibitor, monoclonal antibody, +1 more

5 terms

inducement awards financial

"the Company granted inducement awards to purchase up to 175,000 shares"

Inducement awards are special bonuses given to new employees to encourage them to join a company, often in the form of stock or money. They matter because they can motivate talented people to choose one company over another and help align their success with the company's growth. Think of it like a signing bonus to seal the deal.

NASDAQ Listing Rule 5635(c)(4) regulatory

"Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)"

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

menin inhibitor medical

"Revuforj® (revumenib), an FDA-approved menin inhibitor"

A menin inhibitor is a type of experimental drug that blocks the action of a protein called menin, which some cancers use to keep growing. Think of it as flipping off a switch that cancer cells rely on to survive; by doing so, these drugs can slow or stop tumor growth. Investors watch menin inhibitors because clinical trial results, regulatory approvals, and market demand determine whether they become valuable cancer treatments and potential revenue drivers.

monoclonal antibody medical

"Niktimvo™ (axatilimab-csfr), an FDA-approved monoclonal antibody"

A monoclonal antibody is a laboratory-made protein designed to recognize and attach to a specific target in the body, such as a disease-causing substance or cell. It functions like a highly precise lock-and-key tool, helping to treat or detect illnesses. For investors, companies developing monoclonal antibodies can represent promising opportunities in the healthcare sector, especially as these treatments often address unmet medical needs.

CSF-1 receptor medical

"antibody that blocks the colony stimulating factor 1 (CSF-1) receptor"

A cell-surface protein found mainly on certain immune cells that acts like a lock for signaling molecules such as colony-stimulating factor 1; when those molecules bind, the receptor tells the cell to grow, move or change behavior. As a biological control point in inflammation, tissue repair and some cancers, it is a common drug target; investors watch drug candidates and clinical results involving the receptor because they can affect the commercial and regulatory prospects of biotech companies.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

NEW YORK, Sept. 04, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on September 1, 2026, the Company granted inducement awards to purchase up to 175,000 shares of common stock to nineteen new employees under the Company's 2023 Inducement Plan. The stock options will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the vesting commencement date and 1/48th of the underlying shares vesting monthly thereafter over 36 months, subject to the employee's continued service relationship with Syndax through the applicable vesting dates.

About Syndax
Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company advancing innovative cancer therapies. Highlights of the Company's pipeline include Revuforj^® (revumenib), an FDA-approved menin inhibitor, and Niktimvo™ (axatilimab-csfr), an FDA-approved monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor. Fueled by our commitment to reimagining cancer care, Syndax is working to unlock the full potential of its pipeline and is conducting several clinical trials across the continuum of treatment. For more information, please visit www.syndax.com or follow the Company on X and LinkedIn.

Syndax Contact

Sharon Klahre 
Syndax Pharmaceuticals, Inc. 
sklahre@syndax.com
Tel 781.684.9827

FAQ

What inducement equity grants did Syndax Pharmaceuticals (SNDX) announce on September 4, 2026?

Syndax Pharmaceuticals announced inducement awards of stock options to purchase up to 175,000 shares of common stock. These options were granted on September 1, 2026 to nineteen new employees under the company’s 2023 Inducement Plan.

How do the new Syndax (SNDX) inducement stock options vest?

The Syndax inducement stock options vest over four years. 25% of the shares vest on the one-year anniversary of the vesting commencement date, and the remaining 75% vest in 1/48th monthly installments over the next 36 months, subject to continued service.

Who received the new Syndax Pharmaceuticals (SNDX) inducement stock option grants?

The inducement stock option grants were awarded to nineteen new employees of Syndax Pharmaceuticals as part of their employment, under the company’s 2023 Inducement Plan.

Under which plan were the latest Syndax (SNDX) inducement stock options granted?

The newly announced inducement stock options were granted under Syndax Pharmaceuticals’ 2023 Inducement Plan, which is used to provide equity awards to new employees.